Welcome to our dedicated page for Bristol-Myers Squibb Co. news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co. stock.
Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.
Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.
Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.
Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.
Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.
Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.
Bristol Myers Squibb (NYSE: BMY) released 10-year follow-up data from the CheckMate -067 Phase 3 trial showing continued long-term survival benefits of Opdivo® plus Yervoy® in advanced melanoma patients. At ten years, 43% of patients treated with the combination were still alive, compared to a 1-year survival rate of 25% a decade ago. Results showed a median overall survival (OS) of 71.9 months for the combination therapy, 36.9 months for Opdivo alone, and 19.9 months for Yervoy alone. These findings were presented at the ESMO Congress 2024 and published in The New England Journal of Medicine. The study included 945 patients, highlighting that durable clinical benefits were observed across subgroups, including those with BRAF mutant and wild-type tumors. Safety data showed no new adverse signals, and Grade 3/4 treatment-related adverse events were consistent with prior findings.
Bristol Myers Squibb (NYSE: BMY) has announced that it will release its third quarter 2024 financial results on Thursday, October 31, 2024. The company will host a conference call and live webcast at 8:00 a.m. ET on the same day to discuss the results and address questions from investors and analysts. Interested parties can listen to the webcast at http://investor.bms.com or register for the live call. A replay of the webcast and conference call will be available until November 14, 2024. This announcement provides investors and analysts with an opportunity to gain insights into BMY's financial performance and future outlook.
Bristol Myers Squibb (NYSE: BMY) has announced its latest dividend declarations. The Board of Directors has declared a quarterly dividend of $0.60 per share on the company's common stock, payable on November 1, 2024, to stockholders of record as of October 4, 2024. Additionally, a quarterly dividend of $0.50 per share has been declared on the company's convertible preferred stock, payable on December 2, 2024, to stockholders of record as of November 5, 2024. These dividend announcements demonstrate BMY's commitment to returning value to shareholders and maintaining its dividend program.
Bristol Myers Squibb (NYSE: BMY) announced it will present nearly 60 abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, from September 13-17.
Key highlights include:
- Data from the Phase 2 RELATIVITY-104 trial indicating the efficacy of nivolumab, relatlimab, and chemotherapy as a first-line treatment for stage IV or recurrent NSCLC.
- Plans to initiate Phase 3 RELATIVITY-1093 trial.
- Ten-year follow-up data from CheckMate-067 showing long-term survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) in advanced melanoma.
- Results from early-phase trials supporting BMS's diverse oncology portfolio and novel combinations across a wide range of solid tumors.
An investor webcast will be hosted on September 14 to discuss these advancements.
Bristol Myers Squibb (NYSE: BMY) employees are embarking on the Coast 2 Coast 4 Cancer (C2C4C) cycling event, aiming to raise $1 million for the V Foundation for Cancer Research. The 3,000-mile relay from Oregon to New Jersey involves teams cycling approximately 225 miles each over three days. Since 2014, C2C4C has raised over $12.7 million for cancer research in North America. Bristol Myers Squibb will match donations up to $500,000. The event has expanded globally, with rides in Europe, Japan, and Latin America, contributing to a total of $16 million USD donated worldwide for cancer research. Many participants have personal connections to cancer, riding in memory of loved ones or as survivors themselves.
Bristol Myers Squibb (NYSE: BMY) announced new long-term follow-up results from the EXPLORER-LTE study of CAMZYOS® (mavacamten) in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The data, presented at the European Society of Cardiology Congress, showed consistent and sustained improvements in echocardiographic measures and symptoms after up to 3.5 years of treatment. Key findings include:
- Reductions in left ventricular outflow tract (LVOT) gradients and left atrial volume index
- Decreased NT-proBNP levels
- Improvement in NYHA class, with 66.3% of patients reaching class I at Week 180
- No new safety signals identified
The results reinforce CAMZYOS's established efficacy and safety profile as the first approved cardiac myosin inhibitor for symptomatic oHCM.
Bristol Myers Squibb (NYSE: BMY) has announced its participation in two upcoming investor conferences in September 2024. Christopher Boerner, Board Chair and CEO, and David Elkins, EVP and CFO, will engage in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5 at 1:05 p.m. ET. Adam Lenkowsky, EVP and Chief Commercialization Officer, will participate in a similar session at the 2024 Wells Fargo Healthcare Conference on September 6 at 9:30 a.m. ET.
Both sessions will be accessible to investors and the public via http://investor.bms.com. Archived versions will be available after the events conclude. These conferences provide an opportunity for BMY to address questions about the company and engage with the investment community.
Bristol Myers Squibb (NYSE: BMY) will present research on its cardiovascular portfolio at the European Society of Cardiology (ESC) Congress 2024 in London. Key presentations include:
1. Long-term efficacy and safety data on CAMZYOS® (mavacamten) for obstructive hypertrophic cardiomyopathy (oHCM) up to 3.5 years
2. Pharmacodynamic biomarker analysis for milvexian from the AXIOMATIC-TKR study
3. Gender and racial differences in outcomes for Medicare beneficiaries with non-valvular atrial fibrillation treated with oral anticoagulants, including ELIQUIS® (apixaban)
The presentations demonstrate BMY's commitment to advancing cardiovascular treatments. The company will showcase developments in anticoagulation, thrombosis management, and oHCM treatment.
Bristol Myers Squibb (NYSE: BMY) announced that the FDA has accepted their supplemental Biologics License Application (sBLA) for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a potential first-line treatment for unresectable hepatocellular carcinoma (HCC). The acceptance is based on results from the Phase 3 CheckMate -9DW trial, which showed improved survival compared to lenvatinib or sorafenib. The FDA assigned a target action date of April 21, 2025.
The combination demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS). The safety profile was consistent with previously reported data and manageable with established protocols. This application could potentially bring a new first-line treatment option to HCC patients, addressing an urgent need in this increasing patient population.
Bristol Myers Squibb (NYSE: BMY) announced that the European Medicines Agency (EMA) has validated its application to expand the indication for Breyanzi, a CAR T cell therapy, for treating adult patients with relapsed or refractory follicular lymphoma who have received two or more prior lines of systemic therapy. The application is based on data from the Phase 2 TRANSCEND FL study, which showed high overall response rates with deep and durable responses. Breyanzi demonstrated a consistent and manageable safety profile.
Additionally, Breyanzi received approval in Japan for treating relapsed or refractory follicular lymphoma after one prior line of systemic therapy in high-risk patients and after two or more lines of systemic therapy. This makes it the first CAR T treatment approved for this high-risk population with unmet needs.
FAQ
What is the current stock price of Bristol-Myers Squibb Co. (BMY)?
What is the market cap of Bristol-Myers Squibb Co. (BMY)?
What is Bristol-Myers Squibb's core business?
Where is Bristol-Myers Squibb headquartered?
What was Bristol-Myers Squibb's revenue for fiscal 2022?
What is a significant focus area for Bristol-Myers Squibb?
How much of Bristol-Myers Squibb's total sales come from the U.S. market?
What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?
What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?
What is SpliceCore®?
When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?
What is Bristol-Myers Squibb's mission?
